戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 n for confirmatory test results and to adopt risk-reducing behaviors sooner.
2                            In the absence of risk-reducing behaviors with demonstrable efficacy, here
3 able moment to motivate individuals to adopt risk-reducing behaviors.
4                                              Risk-reducing bilateral salpingo-oophorectomy (RRBSO) an
5 Tamoxifen and Raloxifene, which compares the risk-reducing efficacy as well as toxicity of these two
6 category with the strongest association) for risk-reducing foods or risk-increasing foods, respective
7                                    Potential risk-reducing interventions are recommended for individu
8 sting experience and in the effectiveness of risk-reducing interventions compound access and knowledg
9 k factors for melanoma and comments on which risk-reducing interventions pediatricians should institu
10 group of high-risk women in whom the role of risk-reducing interventions should be explored.
11 umor features and treatments associated with risk-reducing interventions; for example, in most BRCA2
12 able mortality during adulthood, with excess risks reducing life expectancy by as much as 28%.
13                Among 29 individuals choosing risk-reducing mastectomy after testing, two were found t
14  bilateral salpingo-oophorectomy (RRBSO) and risk-reducing mastectomy are widely used for BRCA1 and B
15 cancers were diagnosed in the 247 women with risk-reducing mastectomy compared with 98 women of 1372
16 Among high-risk women and mutation carriers, risk-reducing mastectomy decreased breast cancer by 85%
17 ve shown that the number of women undergoing risk-reducing mastectomy has increased rapidly in the US
18 a contralateral breast cancer, contralateral risk-reducing mastectomy is often, but not universally,
19 y used, this sharp increase in contralateral risk-reducing mastectomy is surprising.
20 ever, many patients undergoing contralateral risk-reducing mastectomy might not be categorised as hig
21  North America to assess the relationship of risk-reducing mastectomy or salpingo-oophorectomy with c
22 n with BRCA1 and BRCA2 mutations, the use of risk-reducing mastectomy was associated with a lower ris
23 iagnosed with breast cancer who did not have risk-reducing mastectomy.
24 on making in prioritization of research into risk-reducing measures, and inform case management in cl
25  the effectiveness of intensive screening or risk-reducing medications in mutation carriers, although
26 ffects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen or raloxife
27 nd testing increased surveillance and led to risk-reducing operations, which resulted in diagnosis of
28                                       Cancer risk-reducing options for BRCA1/2 mutation carriers vary
29 ation of the potential benefit and risk of a risk-reducing procedure in a potentially otherwise healt
30 ough a small rise in the number of bilateral risk-reducing procedures has been noted in high-risk gen
31 fallopian tube carcinomas identified through risk-reducing prophylactic oophorectomy from three women
32 clearly associated with poor compliance with risk-reducing recommendations, with abnormalities in aut
33                                              Risk-reducing salpingo-oophorectomy (RRSO) has been wide
34                                              Risk-reducing salpingo-oophorectomy (RRSO) is effective
35                          Therefore, although risk-reducing salpingo-oophorectomy (RRSO) is standard t
36                                              Risk-reducing salpingo-oophorectomy (RRSO) lowers mortal
37                                              Risk-reducing salpingo-oophorectomy (RRSO) was encourage
38 cancer risks, as well as risk reduction from risk-reducing salpingo-oophorectomy (RRSO), by CJM and s
39 genes, surgical risk reduction, particularly risk-reducing salpingo-oophorectomy (RRSO), has become a
40 n at high risk increasingly choose bilateral risk-reducing salpingo-oophorectomy (RRSO).
41 was diagnosed in 3 of the 98 women who chose risk-reducing salpingo-oophorectomy and peritoneal cance
42 to 100% compared with women without surgery; risk-reducing salpingo-oophorectomy decreased breast can
43 aperitoneal cancer in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy is highly likely the
44                                              Risk-reducing salpingo-oophorectomy is often considered
45             For carriers of these mutations, risk-reducing salpingo-oophorectomy significantly reduce
46 sociated with a lower risk of breast cancer; risk-reducing salpingo-oophorectomy was associated with
47      We prospectively compared the effect of risk-reducing salpingo-oophorectomy with that of surveil
48           Among 90 individuals who underwent risk-reducing salpingo-oophorectomy, one early-stage ova
49      Compared with women who did not undergo risk-reducing salpingo-oophorectomy, undergoing salpingo
50      Compared with women who did not undergo risk-reducing salpingo-oophorectomy, women who underwent
51 malignant appendiceal mucocele 2 years after risk-reducing salpingo-oophorectomy.
52 go either surveillance for ovarian cancer or risk-reducing salpingo-oophorectomy.
53        We used decision analysis to simulate risk-reducing strategies in BRCA1/2 mutation carriers an
54  Hence, colicin expressers may be engaged in risk-reducing strategies-or bet-hedging-as they balance
55  and BRCA2 mutations, and the most effective risk-reducing strategies.
56 isk factors, warranting close monitoring and risk-reducing strategies.
57 s due to slow persister growth pays off as a risk-reducing strategy.
58 intensive cancer screening, medications, and risk-reducing surgery.
59 yndrome who begin regular screening and have risk-reducing surgery.
60  testing, followed by tailored screening and risk-reducing surgery.
61  study evaluated clinical outcomes or use of risk-reducing therapies after screening versus no screen
62  to personalized estimation of benefits from risk-reducing therapies in primary prevention may help t

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。